- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02243371
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
March 17, 2021 updated by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
Stanford, California, United States, 94305
- Stanford University
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Sidney kimmel comprehensive cancer center at johns hopkins
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years.
- Have histologically- or cytologically-proven adenocarcinoma of the pancreas. Patients with mixed histology will be excluded.
- Have metastatic disease.
- Have failed only 1 prior chemotherapy regimen for metastatic pancreatic cancer.
- Patients with the presence of at least one measurable lesion.
- Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator).
- ECOG performance status 0 or 1.
- Life expectancy of greater than 3 months.
- Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
- Must use acceptable form of birth control while on study.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- known history or evidence of brain metastases.
- Had surgery within the last 28 days
- Have received any non-oncology vaccine therapy used for prevention of infectious diseases including seasonal vaccinations within 28 days of study treatment.
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, GVAX or CRS-207
- Systemic steroids within the last 14 days
- Use more than 3 g/day of acetaminophen.
- Patients on immunosuppressive agents.
- Patients receiving growth factors within the last 14 days
- Known allergy to both penicillin and sulfa.
- Severe hypersensitivity reaction to any monoclonal antibody.
- Have artificial joints or implants that cannot be easily removed
- Have any evidence of hepatic cirrhosis or clinical or radiographic ascites.
- Have significant and/or malignant pleural effusion
- Infection with HIV or hepatitis B or C at screening
- Significant heart disease
- Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures
- Unable to avoid intimate contact with another individual known to be at high risk of listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during the course of CRS-207 treatment until completion of antibiotic regimen.
- Are pregnant or breastfeeding.
- Have rapidly progressing disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: CY/ GVAX/ CRS-207/ nivolumab
|
1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
3 mg/kg administered IV on Day 1 of Cycles 1-6
Other Names:
5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
Other Names:
200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
Other Names:
|
Experimental: Arm B: CY/ GVAX/ CRS-207
|
1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
Other Names:
200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 2 years and 7 months
|
OS will be measured from date of randomization until death or end of followup (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis).
|
2 years and 7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity
Time Frame: 2 years and 7 months
|
When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.
|
2 years and 7 months
|
Progression-free Survival (PFS) in Metastatic Pancreatic Cancer Patients
Time Frame: 2 years and 7 months
|
PFS is defined as the number of months from the date of randomization to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause.
Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.
|
2 years and 7 months
|
Immune-related Progression-free Survival (irPFS) by IRRC in Metastatic Pancreatic Cancer Patients
Time Frame: 2 years and 7 months
|
irPFS is defined as the number of months from the date of randomization to disease progression (PD or relapse from CR as assessed using irRC RECIST 1.1 criteria) or death due to any cause.
Per irRC criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in tumor burden compared with baseline, Progressive Disease (PD) is >20% increase in tumor burden compared with nadir, Stable Disease (SD) is <30% decrease in tumor burden compared with baseline or <20% increase in tumor burden compared to nadir.
|
2 years and 7 months
|
Time to Progression (TTP) by RECIST 1.1 in Metastatic Pancreatic Cancer Patients
Time Frame: 2 years and 7 months
|
Time to progression (TTP) is defined as the time from randomization to the date of documented disease progression as defined by RECIST 1.1 criteria.
Individuals are censored at the date of the last radiological assessment that occurs prior to any of the following: death, switch to another anti-cancer therapy, or end of follow-up.
Individuals without follow-up or baseline measurements are censored at 1 day.
Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.
|
2 years and 7 months
|
Number of Participants With Partial Response (PR) or Complete Response (CR) as Defined by RECIST 1.1 in Metastatic Pancreatic Cancer Patients
Time Frame: 2 years and 7 months
|
Per RECIST 1.1 criteria, PR is defined as =>30% decrease in sum of diameters of target lesions and CR is the disappearance of all target lesions.
|
2 years and 7 months
|
Tumor Marker Kinetics (CA 19-9) in Patients With Baseline Abnormal Levels as Measured by Number of Participants With Stable or Responding CA19-9 Concentration
Time Frame: 120 days
|
Number of participants with stable or responding (<50% increase of serum CA19-9 concentration) at 120 days.
|
120 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Dung Le, MD, Johns Hopkins University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2015
Primary Completion (Actual)
July 21, 2017
Study Completion (Actual)
July 21, 2017
Study Registration Dates
First Submitted
September 15, 2014
First Submitted That Met QC Criteria
September 16, 2014
First Posted (Estimate)
September 17, 2014
Study Record Updates
Last Update Posted (Actual)
April 6, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Cyclophosphamide
- Nivolumab
Other Study ID Numbers
- J14113
- ADU-CL-06
- IRB00043936 (Other Identifier: JHMIRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Previously Treated Metastatic Adenocarcinoma of the Pancreas
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Kyowa Hakko Kirin Pharma, Inc.Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
-
Minneamrita Therapeutics LLCRecruitingMetastatic Adenocarcinoma of the PancreasKorea, Republic of
-
IpsenActive, not recruitingMetastatic Adenocarcinoma of the PancreasUnited States, Spain, Hungary, France, Portugal, Korea, Republic of, Germany, United Kingdom, Austria, Italy, Israel, Australia, Brazil, Czechia, Belgium, Russian Federation, Canada, Greece
-
Grupo Gallego de Investigaciones OncologicasCompletedMetastatic Adenocarcinoma of the PancreasSpain
-
NantCell, Inc.TakedaTerminatedCancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine CancerItaly, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
Clinical Trials on CRS-207
-
Anza Therapeutics, Inc.TerminatedCarcinoma, Non-Small-Cell Lung | Adenocarcinoma of the Pancreas | Malignant Epithelial Mesothelioma | Adenocarcinoma of the OvariesIsrael, United States
-
Aduro Biotech, Inc.Merck Sharp & Dohme LLCTerminatedGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Aduro Biotech, Inc.Merck Sharp & Dohme LLCTerminatedMalignant Pleural MesotheliomaUnited States
-
Aduro Biotech, Inc.Incyte CorporationTerminatedPlatinum-resistant Ovarian Cancer | Platinum-resistant Fallopian Cancer | Platinum-resistant Peritoneal CancerUnited States, Canada
-
Orion Corporation, Orion PharmaCompleted
-
Bridge Biotherapeutics, Inc.RecruitingEGFR Mutant Advanced Non-Small Cell Lung CancerKorea, Republic of, United States
-
CAI HongbingRecruitingOvarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer, Epithelial | Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | Homologous Recombination Repair Gene MutationChina
-
University of California, San DiegoRecruitingColorectal Cancer | Ovarian Carcinoma | Peritoneal Metastases | Appendix CancerUnited States
-
Sientra, Inc.TerminatedBreast Augmentation | Breast Revision-AugmentationUnited States
-
Uppsala University HospitalRecruitingColorectal Cancer, Peritoneal Carcinomatosis, Anastomosis InsufficiencySweden